Premium Nahrungsergänzungsmittel | artgerecht

Hepatorenal Syndrome – Causes, Symptoms and Treatment

Hepatorenal syndrome (HRS) is a severe form of kidney failure occurring in patients with advanced liver disease. It is caused by circulatory disturbances and is life-threatening without prompt treatment.

Regular tips about health Regular tips about health

Things worth knowing about "Hepatorenal Syndrome"

Hepatorenal syndrome (HRS) is a severe form of kidney failure occurring in patients with advanced liver disease. It is caused by circulatory disturbances and is life-threatening without prompt treatment.

What is Hepatorenal Syndrome?

Hepatorenal syndrome (HRS) is a serious and potentially life-threatening complication of advanced liver disease, characterized by the rapid deterioration of kidney function. Despite structurally normal kidneys, the organs fail due to severely impaired blood circulation caused by the underlying liver condition. HRS most commonly affects patients with liver cirrhosis, severe alcoholic hepatitis, or acute liver failure and represents a medical emergency requiring immediate intervention.

Causes and Pathophysiology

HRS develops as a result of complex circulatory changes triggered by impaired liver function:

Portal hypertension: Increased pressure in the portal venous system causes dilation of the splanchnic blood vessels in the abdominal cavity.
Reduced effective circulating volume: Blood pools in the dilated abdominal vessels, leading to decreased perfusion of vital organs, including the kidneys.
Activation of vasoconstrictors: In response, the body releases vasoconstrictive hormones such as renin, aldosterone, and noradrenaline, which further reduce renal blood flow.
Triggering factors: Infections (especially spontaneous bacterial peritonitis), gastrointestinal bleeding, excessive diuretic use, or large-volume paracentesis without adequate albumin supplementation can precipitate HRS.

Types of Hepatorenal Syndrome

Current classifications distinguish two main types:

HRS Type 1 (HRS-AKI): Rapid, acute kidney injury with a significant rise in serum creatinine within days. This type is particularly life-threatening and requires immediate intensive care.
HRS Type 2 (HRS-CKD): A slower, chronic course with moderate kidney impairment, often associated with refractory ascites. The prognosis is somewhat better than Type 1, though still serious.

Symptoms

Symptoms of HRS are often non-specific and may overlap with signs of the underlying liver disease:

Markedly reduced urine output (oliguria or anuria)
Rising serum creatinine and blood urea nitrogen (BUN)
Fluid retention (ascites, peripheral edema)
Confusion and altered consciousness (hepatic encephalopathy)
Jaundice (icterus)
Low blood pressure and circulatory instability

Diagnosis

HRS is diagnosed based on clinical and laboratory criteria according to internationally recognized guidelines (e.g., from the International Ascites Club):

Presence of cirrhosis or acute liver failure
Rise in serum creatinine (typically above 1.5 mg/dL or an increase of more than 0.3 mg/dL within 48 hours)
Exclusion of other causes of kidney failure (e.g., hypovolemia, shock, nephrotoxic drugs, structural kidney disease)
No improvement in kidney function after volume expansion with albumin infusion

Additional investigations include urinalysis, renal ultrasound, and comprehensive blood tests.

Treatment

Treatment of HRS must be initiated promptly and aims to improve renal perfusion while stabilizing liver function:

Pharmacological Therapy

Terlipressin (a vasopressin analogue) is the first-line treatment: it constricts the dilated splanchnic vessels, thereby improving kidney perfusion.
Albumin infusions are given alongside to increase effective circulating volume.
Where terlipressin is unavailable, noradrenaline or the combination of midodrine and octreotide may be used as alternatives.

Renal Replacement Therapy

In advanced kidney failure, temporary dialysis may be required as a bridge to liver transplantation.

Liver Transplantation

Liver transplantation is the only curative treatment. By addressing the underlying cause, it leads to full recovery of kidney function in most cases, provided no permanent kidney damage has occurred.

Transjugular Intrahepatic Portosystemic Shunt (TIPS)

In selected cases, a TIPS procedure may be considered to reduce portal pressure and improve circulatory hemodynamics.

Prognosis

Without treatment, the prognosis of HRS is very poor. Type 1 HRS has a median survival of only a few weeks without therapy. However, with modern pharmacological treatment and timely liver transplantation, survival rates can be significantly improved. Early recognition and rapid initiation of treatment are critical to patient outcomes.

References

European Association for the Study of the Liver (EASL) - Clinical Practice Guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. Journal of Hepatology, 2018.
Ginès P, Krag A, Abraldes JG, Solà E, Martin-Llahi M, Kamath PS - Liver cirrhosis. The Lancet, 2021.
Nadim MK, Kellum JA, Forni L, et al. - Acute kidney injury in patients with cirrhosis: ADQI consensus recommendations. Gut, 2021.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.

Most read entries

3 Posts in this encyclopedia category